Carillon Tower Advisers’s Novartis NVS Stock Holding History

Carillon Tower Advisers’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$7.17M	Sell	75,878 -6,261	-8%	-$547K	0.04%	364
2020 Q3	$7.14M	Sell	82,139 -5,594	-6%	-$485K	0.1%	294
2020 Q2	$7.66M	Buy	87,733 +603	+0.7%	+$52.1K	0.06%	325
2020 Q1	$7.18M	Sell	87,130 -1,518	-2%	-$135K	0.07%	308
2019 Q4	$8.39M	Sell	88,648 -3,444	-4%	-$309K	0.06%	352
2019 Q3	$8M	Sell	92,092 -94,715	-51%	-$8.5M	0.06%	356
2019 Q2	$17.1M	Sell	186,807 -117,547	-39%	-$9.95M	0.12%	270
2019 Q1	$26.2M	Buy	304,354 +28,567	+10%	+$2.29M	0.19%	200
2018 Q4	$21.2M	Sell	275,787 -48,614	-15%	-$3.78M	0.18%	208
2018 Q3	$25M	Buy	324,401 +141,755	+78%	+$10.5M	0.18%	202
2018 Q2	$12.4M	Buy	182,646 +26,344	+17%	+$1.82M	0.1%	297
2018 Q1	$11.3M	Buy	+156,302	New	+$11.9M	0.09%	289

Other funds holding NVS

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.7B AUM 13.92% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $14.7B AUM 12.5% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Carillon Tower Advisers's NVS Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Novartis (NVS) stake by 7.6% in Q4 2020, selling an estimated $547K and leaving 75,878 shares worth $7.17M. The position accounts for 0.04% of the portfolio, ranked #364.

Carillon Tower Advisers first reported a position in NVS in Q1 2018 and has held it in 12 quarters since. The position peaked at $26.2M in Q1 2019. 1,177 funds tracked by Wall St. Rank hold NVS as of Q4 2020.

Carillon Tower Advisers held 75,878 shares of Novartis worth $7.17M as of Q4 2020.
Carillon Tower Advisers sold 6,261 Novartis shares in Q4 2020, an estimated $547K.
Novartis made up 0.04% of Carillon Tower Advisers's portfolio in Q4 2020, its #364 holding.
Carillon Tower Advisers first reported a position in Novartis in Q1 2018 and has held it in 12 quarters since.
Carillon Tower Advisers's Novartis position peaked at $26.2M in Q1 2019.
1,177 funds tracked by Wall St. Rank held Novartis as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.